1. Home
  2. GH vs KD Comparison

GH vs KD Comparison

Compare GH & KD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Guardant Health Inc.

GH

Guardant Health Inc.

HOLD

Current Price

$85.48

Market Cap

13.3B

Sector

Health Care

ML Signal

HOLD

Logo Kyndryl Holdings Inc.

KD

Kyndryl Holdings Inc.

HOLD

Current Price

$12.35

Market Cap

2.8B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
GH
KD
Founded
2011
2020
Country
United States
United States
Employees
N/A
80000
Industry
Medical Specialities
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
13.3B
2.8B
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
GH
KD
Price
$85.48
$12.35
Analyst Decision
Strong Buy
Buy
Analyst Count
20
5
Target Price
$117.80
$35.25
AVG Volume (30 Days)
1.6M
4.7M
Earning Date
05-11-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
6.74
170.95
EPS
N/A
0.77
Revenue
$982,021,000.00
$15,057,000,000.00
Revenue This Year
$33.40
$3.96
Revenue Next Year
$28.55
$0.41
P/E Ratio
N/A
$16.31
Revenue Growth
32.88
N/A
52 Week Low
$36.36
$10.10
52 Week High
$120.74
$43.74

Technical Indicators

Market Signals
Indicator
GH
KD
Relative Strength Index (RSI) 30.55 33.95
Support Level $54.39 $11.34
Resistance Level $103.16 $13.81
Average True Range (ATR) 4.09 0.51
MACD -0.81 0.45
Stochastic Oscillator 19.47 42.98

Price Performance

Historical Comparison
GH
KD

About GH Guardant Health Inc.

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

About KD Kyndryl Holdings Inc.

Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives. The company's reportable segments consist of the following: Principal Markets which represents its operations in operations in Australia / New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, and the United Kingdom / Ireland, United States, Japan, and Strategic Markets. It derives maximum revenue from the United States.

Share on Social Networks: